FBIO Quote, Financials, Valuation and Earnings

Apellis Pharmaceuticals, Inc. has a net margin of 50.07% compared to Fortress Biotech, Inc.'s net margin of 47.04%. Fortress Biotech, Inc.'s return on equity of -223.06% beat Apellis Pharmaceuticals, Inc.'s return on equity of 18.94%.

Fortress Biotech, Inc. has a consensus price target of $10.75, signalling upside risk potential of 299.63%. On the other hand Apellis Pharmaceuticals, Inc. has an analysts' consensus of $35.39 which suggests that it could grow by 66.54%. Given that Fortress Biotech, Inc. has higher upside potential than Apellis Pharmaceuticals, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Apellis Pharmaceuticals, Inc..

Fortress Biotech, Inc. has a beta of 1.490, which suggesting that the stock is 49.031% more volatile than S&P 500. In comparison Apellis Pharmaceuticals, Inc. has a beta of 0.368, suggesting its less volatile than the S&P 500 by 63.199%.

Fortress Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apellis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech, Inc. pays 3.9% of its earnings as a dividend. Apellis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortress Biotech, Inc. quarterly revenues are $17.6M, which are smaller than Apellis Pharmaceuticals, Inc. quarterly revenues of $458.6M. Fortress Biotech, Inc.'s net income of $8.8M is lower than Apellis Pharmaceuticals, Inc.'s net income of $215.7M. Notably, Fortress Biotech, Inc.'s price-to-earnings ratio is -- while Apellis Pharmaceuticals, Inc.'s PE ratio is 71.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech, Inc. is 1.27x versus 2.65x for Apellis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Axsome Therapeutics, Inc. has a net margin of 50.07% compared to Fortress Biotech, Inc.'s net margin of -27.62%. Fortress Biotech, Inc.'s return on equity of -223.06% beat Axsome Therapeutics, Inc.'s return on equity of -327.97%.

Fortress Biotech, Inc. has a consensus price target of $10.75, signalling upside risk potential of 299.63%. On the other hand Axsome Therapeutics, Inc. has an analysts' consensus of $181.31 which suggests that it could grow by 21.6%. Given that Fortress Biotech, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Axsome Therapeutics, Inc..

Fortress Biotech, Inc. has a beta of 1.490, which suggesting that the stock is 49.031% more volatile than S&P 500. In comparison Axsome Therapeutics, Inc. has a beta of 0.476, suggesting its less volatile than the S&P 500 by 52.416%.

Fortress Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech, Inc. pays 3.9% of its earnings as a dividend. Axsome Therapeutics, Inc. pays out -- of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortress Biotech, Inc. quarterly revenues are $17.6M, which are smaller than Axsome Therapeutics, Inc. quarterly revenues of $171M. Fortress Biotech, Inc.'s net income of $8.8M is higher than Axsome Therapeutics, Inc.'s net income of -$47.2M. Notably, Fortress Biotech, Inc.'s price-to-earnings ratio is -- while Axsome Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech, Inc. is 1.27x versus 12.96x for Axsome Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Journey Medical Corp. has a net margin of 50.07% compared to Fortress Biotech, Inc.'s net margin of -13.13%. Fortress Biotech, Inc.'s return on equity of -223.06% beat Journey Medical Corp.'s return on equity of -44.34%.

Fortress Biotech, Inc. has a consensus price target of $10.75, signalling upside risk potential of 299.63%. On the other hand Journey Medical Corp. has an analysts' consensus of $13.50 which suggests that it could grow by 75.55%. Given that Fortress Biotech, Inc. has higher upside potential than Journey Medical Corp., analysts believe Fortress Biotech, Inc. is more attractive than Journey Medical Corp..

Fortress Biotech, Inc. has a beta of 1.490, which suggesting that the stock is 49.031% more volatile than S&P 500. In comparison Journey Medical Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Fortress Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Journey Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech, Inc. pays 3.9% of its earnings as a dividend. Journey Medical Corp. pays out -- of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortress Biotech, Inc. quarterly revenues are $17.6M, which are smaller than Journey Medical Corp. quarterly revenues of $17.6M. Fortress Biotech, Inc.'s net income of $8.8M is higher than Journey Medical Corp.'s net income of -$2.3M. Notably, Fortress Biotech, Inc.'s price-to-earnings ratio is -- while Journey Medical Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech, Inc. is 1.27x versus 3.01x for Journey Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical, Inc. has a net margin of 50.07% compared to Fortress Biotech, Inc.'s net margin of -112.81%. Fortress Biotech, Inc.'s return on equity of -223.06% beat Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83%.

Fortress Biotech, Inc. has a consensus price target of $10.75, signalling upside risk potential of 299.63%. On the other hand Ultragenyx Pharmaceutical, Inc. has an analysts' consensus of $81.85 which suggests that it could grow by 124.55%. Given that Fortress Biotech, Inc. has higher upside potential than Ultragenyx Pharmaceutical, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Ultragenyx Pharmaceutical, Inc..

Fortress Biotech, Inc. has a beta of 1.490, which suggesting that the stock is 49.031% more volatile than S&P 500. In comparison Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.763%.

Fortress Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech, Inc. pays 3.9% of its earnings as a dividend. Ultragenyx Pharmaceutical, Inc. pays out -- of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortress Biotech, Inc. quarterly revenues are $17.6M, which are smaller than Ultragenyx Pharmaceutical, Inc. quarterly revenues of $159.9M. Fortress Biotech, Inc.'s net income of $8.8M is higher than Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M. Notably, Fortress Biotech, Inc.'s price-to-earnings ratio is -- while Ultragenyx Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech, Inc. is 1.27x versus 5.64x for Ultragenyx Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.